About
Autoimmune Therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalNorth & South Carolina
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
600
By Phase
PHASE2: 3PHASE3: 2
By Status
RECRUITING: 2COMPLETED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06978725Lead Sponsor
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
PHASE2Recruiting
28 participants
Started: Apr 9, 2025 · Completed: Dec 31, 2026
NCT06431373Lead Sponsor
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
PHASE3Recruiting
300 participants
Started: Sep 11, 2024 · Completed: Feb 1, 2028
NCT06433999Lead Sponsor
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
PHASE2Completed
5 participants
Started: Aug 28, 2024 · Completed: Feb 28, 2025
NCT05523765Lead Sponsor
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
PHASE2Completed
26 participants
Started: Nov 14, 2022 · Completed: Jul 30, 2024
NCT05437263Lead Sponsor
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
PHASE3Active, not recruiting
241 participants
Started: Oct 31, 2022 · Completed: Jul 31, 2026
Locations (1)
Headquarters
Durham, NC, United States
Map
Loading map...